QL-X-138

• CAT Number: I044367
• CAS Number: 1469988-63-3
• Molecular Formula: C25H19N5O2
• Molecular Weight: 421.45
• Purity: ≥95%
• Synonyms: N-[2-methyl-5-[2-oxo-9-(1H-pyrazol-4-yl)benzo[h][1,6]naphthyridin-1-yl]phenyl]prop-2-enamide
• InChI: InChI=1S/C25H19N5O2/c1-3-23(31)29-22-11-19(7-4-15(22)2)30-24(32)9-6-17-12-26-21-8-5-16(10-20(21)25(17)30)18-13-27-28-14-18/h3-14H,1H2,2H3,(H,27,28)(H,29,31)
• InChIKey: JMVDIGHUQAXWIE-UHFFFAOYSA-N
• SMILES: CC1=C(C=C(C=C1)N2C(=O)C=CC3=CN=C4C=CC(=CC4=C32)C5=CNN=C5)NC(=O)C=C

QL-X-138（Cat No.:I044367）is a dual inhibitor targeting both Bruton’s tyrosine kinase (BTK) and the interleukin-2-inducible T-cell kinase (ITK), two critical non-receptor tyrosine kinases involved in B-cell and T-cell receptor signaling, respectively. By simultaneously inhibiting BTK and ITK, QL-X-138 modulates immune cell activity, offering potential therapeutic benefits in B-cell malignancies and autoimmune disorders. It has demonstrated potent anti-proliferative effects in preclinical models of chronic lymphocytic leukemia (CLL) and other hematologic cancers. QL-X-138’s dual-target mechanism allows it to suppress both tumor growth and inflammatory responses, making it a promising candidate in immuno-oncology and immunomodulation research.